Alexander J Dwyer
Overview
Explore the profile of Alexander J Dwyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitchell J, Spanier J, Dwyer A, Knutson T, Alkhatib M, Qian G, et al.
Immunity
. 2024 Aug;
57(10):2399-2415.e8.
PMID: 39214091
T cell-mediated islet destruction is a hallmark of autoimmune diabetes. Here, we examined the dynamics and pathogenicity of CD4 T cell responses to four different insulin-derived epitopes during diabetes initiation...
2.
Dwyer A, Shaheen Z, Fife B
Front Immunol
. 2024 Aug;
15:1440045.
PMID: 39211046
Autoimmune diabetes is a disease characterized by the selective destruction of insulin-secreting β-cells of the endocrine pancreas by islet-reactive T cells. Autoimmune disease requires a complex interplay between host genetic...
3.
Spanier J, Fung V, Wardell C, Alkhatib M, Chen Y, Swanson L, et al.
J Clin Invest
. 2023 Aug;
133(18).
PMID: 37561596
Adoptive immunotherapy with Tregs is a promising approach for preventing or treating type 1 diabetes. Islet antigen-specific Tregs have more potent therapeutic effects than polyclonal cells, but their low frequency...
4.
Spanier J, Fung V, Wardell C, Alkhatib M, Chen Y, Swanson L, et al.
bioRxiv
. 2023 Mar;
PMID: 36865264
Brief Summary: Chimeric antigen receptor Tregs specific for an insulin B-chain peptide presented by MHC class II prevent autoimmune diabetes.
5.
Dwyer A, Ritz J, Mitchell J, Martinov T, Alkhatib M, Silva N, et al.
Sci Rep
. 2021 Aug;
11(1):17142.
PMID: 34433860
The notion that T cell insulitis increases as type 1 diabetes (T1D) develops is unsurprising, however, the quantitative analysis of CD4 and CD8 T cells within the islet mass is...
6.
Tucker C, Dwyer A, Fife B, Martinov T
Curr Diab Rep
. 2021 May;
21(6):20.
PMID: 33956235
Purpose Of Review: Programmed death-1 (PD-1) is an inhibitory receptor that controls T and B cell proliferation and function through interacting with its ligand PD-L1 or PD-L2. PD-1/PD-L1 blockade reboots...
7.
Tucker C, Mitchell J, Martinov T, Burbach B, Beura L, Wilson J, et al.
J Immunol
. 2020 Aug;
205(5):1449-1460.
PMID: 32737148
Optimal ex vivo expansion protocols of tumor-specific T cells followed by adoptive cell therapy must yield T cells able to home to tumors and effectively kill them. Our previous study...
8.
Dirice E, Kahraman S, De Jesus D, El Ouaamari A, Basile G, Baker R, et al.
Nat Metab
. 2019 Aug;
1(5):509-518.
PMID: 31423480
Type 1 diabetes (T1D) is characterized by pancreatic islet infiltration by autoreactive immune cells and a near-total loss of β-cells. Restoration of insulin-producing β-cells coupled with immunomodulation to suppress the...
9.
Martinov T, Swanson L, Breed E, Tucker C, Dwyer A, Johnson J, et al.
J Immunol
. 2019 Jul;
203(4):844-852.
PMID: 31324724
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and although numerous patients respond, some develop autoimmune-like symptoms or overt autoimmunity characterized...
10.
McNeel D, Chen Y, Gulley J, Dwyer A, Madan R, Carducci M, et al.
Hum Vaccin Immunother
. 2015 Jun;
11(10):2469-74.
PMID: 26111351
Unlabelled: Anti-tumor vaccines have demonstrated efficacy in patients with castration-resistant metastatic prostate cancer. One vaccine, Prostvac-VF®, using a heterologous prime-boost strategy with vaccinia and fowlpox viral vectors encoding PSA, is...